Journal article
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design
- Abstract:
-
Background Exercise may improve fatigue in multiple myeloma survivors, but trial evidence is limited, and exercise may be perceived as risky in this older patient group with osteolytic bone destruction.
Methods In this Phase 2 Zelen trial, multiple myeloma survivors who had completed treatment at least 6 weeks ago, or were on maintenance only, were enrolled in a cohort study and randomly assigned to usual care or a 6-month exercise programme of tailored aerobic and resistance training. Outcome assessors and usual care participants were masked. The primary outcome was the FACIT-F fatigue score with higher scores denoting less fatigue.
Results During 2014–2016, 131 participants were randomised 3:1 to intervention (n = 89) or usual care (n = 42) to allow for patients declining allocation to the exercise arm. There was no difference between groups in fatigue at 3 months (between-group mean difference: 1.6 [95% CI: −1.1–4.3]) or 6 months (0.3 [95% CI: −2.6–3.1]). Muscle strength improved at 3 months (8.4 kg [95% CI: 0.5–16.3]) and 6 months (10.8 kg [95% CI: 1.2–20.5]). Using per-protocol analysis, cardiovascular fitness improved at 3 months (+1.2 ml/kg/min [95% CI: 0.3–3.7]). In participants with clinical fatigue (n = 17), there was a trend towards less fatigue with exercise over 6 months (6.3 [95% CI: −0.6–13.3]). There were no serious adverse events.
Conclusion Exercise appeared safe and improved muscle strength and cardiovascular fitness, but benefits in fatigue appeared limited to participants with clinical fatigue at baseline. Future studies should focus on patients with clinical fatigue.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Supplementary materials, 81.6KB, Terms of use)
-
(Preview, Supplementary materials, 131.3KB, Terms of use)
-
(Preview, Supplementary materials, 890.3KB, Terms of use)
-
(Preview, Version of record, 581.2KB, Terms of use)
-
- Publisher copy:
- 10.1038/s41416-020-0866-y
Authors
- Publisher:
- Springer Nature
- Journal:
- British Journal of Cancer More from this journal
- Volume:
- 123
- Issue:
- 2
- Pages:
- 187–195
- Publication date:
- 2020-05-21
- Acceptance date:
- 2020-02-26
- DOI:
- ISSN:
-
0007-0920
- Language:
-
English
- Keywords:
- Pubs id:
-
1096568
- Local pid:
-
pubs:1096568
- Deposit date:
-
2020-03-25
Terms of use
- Copyright holder:
- Koutoukidis et al.
- Copyright date:
- 2020
- Rights statement:
- © The Authors 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record